Okairos (Switzerland) a biopharmaceutical company using adenovirus-based technology to focus on T-cell vaccines has closed a €7.2M Series A financing. The deal was led by Life Science Partners and Biomedinvest and was joined by the Novartis Venture Fund.

AlphaVax (Durham, NC) a developer of vaccine products for infectious diseases (influenza & cytomegalovirus lead), biodefense and cancer, has raised approximately $12.65 million in Series E funding. Investors have not been disclosed.

Juvaris BioTherapeutics (Pleasanton, CA) an oncology and anti-infective vaccine platform technology closed on $6M of a $12M Series A led by Kleiner Perkins.

Variation Biotechnologies (Ottawa, Canada) a maker of vaccines for infectious diseases, has raised US$35.7M in Series A funding. The deal was lead by Clarus Ventures with participation from Arch Venture Partners and 5AM Ventures.